SAITAMA MEDICAL UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160002734 | METHOD FOR EVALUATING SIDE-EFFECT ONSET RISK IN ANTICANCER DRUG TREATMENT, INCLUDING DETECTING MUC4 GENE POLYMORPHISM - The purpose of the present invention is to provide an evaluation method kit for evaluating the risk of onset of diffuse alveolar damage due to such factors as anticancer drug administration. The purpose of the present invention is also to provide a method for evaluating the risk of onset of side effects in anticancer drug treatment. An evaluation method and evaluation kit for evaluating the risk of onset of diffuse alveolar damage, including detecting gene polymorphism present in the MUC4 gene. A method for evaluating the risk of onset of side effect in anticancer drug treatment, including detecting gene polymorphism present in the MUC4 gene of a patient scheduled for anticancer drug administration. | 01-07-2016 |
20150352132 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE - It is an object of the present invention to provide a novel therapeutic agent for demyelinating disease which has an action to suppress demyelination of nerve axons. According to the present invention, a therapeutic agent for demyelinating disease which comprises cyclic phosphatidic acids, carba-cyclic phosphatidic acids, thia-cyclic phosphatidic acids, or a salt thereof is provided. | 12-10-2015 |
20150275171 | Method for Producing Pluripotent Stem Cells - The present invention allows a TET1 protein to be more stably expressed in human pluripotent stem cells than in the past by, inter alia, substituting the second amino acid from the amino terminal of a TET1 protein with a different amino acid. Furthermore upon differentiation of said pluripotent stem cells, it is possible to quickly eliminate the expression of, inter alia, NANOG, which is an inhibitor of differentiation and promote the expression of factors related to differentiation by introducing a variant TET1 protein to a pluripotent stem cell. The present invention provides a method for manufacturing pluripotent stem cells with increased differentiation potential, and a substance that is useful to said method. | 10-01-2015 |
20150045244 | METHOD FOR DETERMINING RHEUMATOID ARTHRITIS ACTIVITY INDICATOR, AND BIOMARKER USED THEREIN - The object of the invention is to find a simple biomarker with high reproducibility with regard to a method for evaluating the activity of the condition and progression of rheumatoid arthritis disease and provide an effective evaluation method therefor. The invention is to provide a method for determining the value of a rheumatoid arthritis-linked indicator in a subject, the method being characterized by comprising a step for measuring the amount of expression of the FAM20A gene in blood collected from the subject, a step for analyzing the measured amount of expression using a gene expression profile that is prepared in advance and correlates with the indicator and a step for estimating the value of the indicator in the subject on the basis of the analysis results. | 02-12-2015 |
20140286978 | CYTOTOXIC T LYMPHOCYTE INDUCER - The invention provides a cytotoxic T lymphocyte inducer comprising a virus-like particle composed of VP1 of simian virus 40. The T cell epitope peptide is inserted into a DE loop and/or an HI loop of the VP1. | 09-25-2014 |
20140030742 | ANTIBODY REACTING WITH NATIVE COCHLIN-TOMOPROTEIN (CTP) AND METHOD FOR MEASURING CTP USING SAME - An immunological measurement is performed using anti-CTP antibody characterized by recognizing an antigenic determinant included in the polypeptide represented by amino acid numbers 118-132 of SEQ ID NO: 1, and reacting with native Cochlin-tomoprotein (CTP). | 01-30-2014 |
20130252241 | METHOD OF DISTINGUISHING INFLAMMATORY PATHOGEN CAUSING ACUTE RESPIRATORY INFECTION - The present invention provides a method of distinguishing a respiratory pathogen causing acute respiratory infection, wherein a pathogen to be distinguished is a pathogen colonizing the respiratory tract, the method comprising: | 09-26-2013 |
20130183376 | HEPATITIS C VIRUS LIPOSOME VACCINE - The present invention provides a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis C virus NS3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic T lymphocytes, the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer, and the peptide is bound to the surface of the liposome; a cytotoxic T lymphocyte activator containing the peptide-bound liposome; and a hepatitis C virus vaccine. | 07-18-2013 |
20130011921 | METHOD FOR PRODUCTION OF ARTIFICIAL PLURIPOTENT STEM CELL - Disclosed is a method for producing an iPS cell having a very similar gene expression pattern to that of an ES cell with high efficiency. Specifically disclosed is a method for producing an artificial pluripotent stem cell (an iPS cell), which comprises the steps of: introducing a pluripotency-inducing factor comprising at least an Myc family gene or an Myc family protein into a somatic cell; and culturing the somatic cell in the presence of a sirtuin inhibitor and/or a poly-ADP ribose polymerase (PARP) inhibitor. | 01-10-2013 |
20120281816 | PHASE CONTROLLER - A reflection surface | 11-08-2012 |
20120214183 | METHODS FOR EVALUATING RISK OF MOTHER'S MILK OR FOOD INDUCING AN ONSET OF ATOPIC DERMATITIS, AND MOTHER'S MILK OR FOOD WITH REDUCED RISK OF INDUCING AN ONSET OF ATOPIC DERMATITIS - An entity of a Th2 adjuvant activity in mother's milk has been revealed as coenzyme A by HPLC and mass spectrometry. The followings have been found out that: a risk of developing atopic dermatitis can be evaluated by targeting coenzyme A; and any one of a food and mother's milk with a reduced risk of developing atopic dermatitis can be prepared by removing or inactivating coenzyme A. | 08-23-2012 |
20120129880 | METHOD FOR DETERMINING SENSITIVITY TO IRINOTECAN AND USE THEREOF - To provide a method for determining the sensitivity of a patient to irinotecan, SN-38, and/or a salt thereof, which method can determine the therapeutic response of the patient and to provide a novel cancer therapeutic means employing the method. | 05-24-2012 |
20110262529 | CYTOTOXIC T CELL EPITOPE PEPTIDE FOR SARS CORONAVIRUS, AND USE THEREOF - The present invention aims to provide a novel CTL epitope peptide of the SARS coronavirus. The present invention provides a peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 11, 12, 13, 15, 17, 18, 23 and 24. | 10-27-2011 |
20110091886 | METHOD OF DISTINGUISHING INFLAMMATORY PATHOGEN CAUSING ACUTE RESPIRATORY INFECTION - Disclosed is a method of distinguishing an inflammatory pathogen causing acute respiratory infection wherein the pathogen to be distinguished is a pathogen residing in the respiratory tract, which comprises: (a) a step for counting gene copies originating in subject cells in DNA prepared from a specimen containing secretion from the respiratory tract of the subject; (b) a step for counting the gene copies originating in the pathogen in the DNA; (c) a step for calculating the relative value of count of the gene copies originating in the pathogen to the count of the gene copies originating in the subject cells; and (d) a step for distinguishing whether the pathogen is an inflammatory pathogen causing the disease or not based on the distinguishing standard and the relative value. | 04-21-2011 |
20110081717 | DOUBLE-STRANDED NUCLEIC ACID MOLECULE, CANCER CELL PROLIFERATION INHIBITOR AND PHARMACEUTICAL AGENT SUITABLE FOR PREVENTION OR TREATMENT OF CANCER - A double-stranded nucleic acid molecule including (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 21, and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a), wherein the double-stranded nucleic acid molecule is for suppressing the expression of at least one of APP and EBAG9 genes. | 04-07-2011 |
20100173405 | Double-Stranded Nucleic Acid Molecule Cancer Cell Proliferation Inhibitor and Pharmaceutical Agent Suitable for Prevention or Treatment of Uterine Cancer, Breast Cancer, and Bladder Cancer - A double-stranded nucleic acid molecule for suppressing the expression of at least one of COX7RP and Efp genes which includes (a) a sense strand which includes a nucleotide sequence corresponding to a target sequence indicated by any one of SEQ ID Nos.: 1 to 38 and (b) an antisense strand which includes a nucleotide sequence complementary to that of the sense strand specified in (a); a cancer cell proliferation inhibitor with the double-stranded nucleic acid molecule and against at least one of uterine, breast and bladder cancer cells; and a pharmaceutical agent with the cancer cell proliferation inhibitor and against at least one of uterine, breast and bladder cancers. | 07-08-2010 |
20100136098 | AVIAN INFLUENZA VACCINE - The present invention provides an avian influenza vaccine containing a peptide-bound liposome wherein;
| 06-03-2010 |
20090155782 | Homoeologous Region Determining Method by Homo Junction Fingerprint Method, Homoeologous Region Determining Device, and Gene Screening Method - To provide a method for efficiently searching for a recessive disease gene without needing any pedigree analysis. In a homoeologous region determining method, the following steps are conducted. It is determined whether or not the base constituting a polymorphic marker of a sample DNA of diploid or higher polyploidy is a homojunction. Homojunction region information representing the region of the sample DNA where polymorphic markers determined as continuous homojunctions acquired. If the continuous probability and/or continuous distance of the polymorphic markers contained in the homojunction region information satisfy a predetermined determination condition, the homojunction region is determined as a homoeologous region. A homoeologous region determining device and a gene screening method for identifying a disease susceptibility gene from the determined homoeologous region are also provided. | 06-18-2009 |